Revenue
11.4 million USD
2026 Q2 · USD
Exact inputs and evidence
- Revenue: 11407000 USD Source
Fundies. English
MedTech Acquisition Corporation
EDGARAnnual consolidated revenue for 2025: about USD 45.15M, using the latest reported figures. The previous period, 2024, was about USD 29.43M.
Latest quarter
Operating margin
-86.03%
2026 Q2 · %
Operating cash flow
-10.1 million USD
2026 Q2 · USD
Free cash flow
-10.2 million USD
2026 Q2 · USD
- Cash and cash equivalents
- 46.3 million USD Source
Exact value
46288000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 61.5 million shares Source
Exact value
61469572 shares
Reported share-count change
61.83% · 23.5 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-06.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 4 of 11 periods available· newest 2025-12-31
- Operating income: 4 of 11 periods available· newest 2025-12-31
- Net income: 4 of 11 periods available· newest 2025-12-31
- Operating cash flow: 4 of 11 periods available· newest 2025-12-31
- Capital expenditure: 4 of 11 periods available· newest 2025-12-31
- Total assets: 4 of 11 periods available· newest 2025-12-31
- Total liabilities: 4 of 11 periods available· newest 2025-12-31
- Current assets: 4 of 11 periods available· newest 2025-12-31
- Current liabilities: 4 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 4 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+53.4%Prior period
USD 29.43 million
–
Current period
USD 45.15 million
–
Exact inputs and evidence
45151000 − 29431000 = 15720000 USD
29431000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source45151000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 9.18 millionPrior period
−USD 30.05 million
–
Current period
−USD 39.23 million
–
Exact inputs and evidence
-39227000 − -30045000 = -9182000 USD
-30045000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-39227000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 22.83 millionPrior period
−USD 40.84 million
–
Current period
−USD 18.01 million
–
Exact inputs and evidence
-18012000 − -40843000 = 22831000 USD
-40843000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-18012000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+166.1%Prior period
USD 345,000
–
Current period
USD 918,000
–
Exact inputs and evidence
918000 − 345000 = 573000 USD
345000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source918000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 45.15 million 100% of revenue
- Operating costs Derived USD 72.1 million 160% of revenue
- Operating income −USD 26.95 million −60% of revenue
- Tax, interest and other Derived USD 12.28 million 27% of revenue
- Net income −USD 39.23 million −87% of revenue
Cash
- Operating cash flow −USD 18.01 million −40% of revenue
- Capital expenditure USD 918,000 2% of revenue
- Free cash flow Derived −USD 18.93 million −42% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2022 Operating loss: operating costs were 394% of revenue.
- 2023 Operating loss: operating costs were 394% of revenue.
- 2024 Operating loss: operating costs were 223% of revenue.
- 2025 Operating loss: operating costs were 160% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | 12398000 | 48837000 Derived | -36439000 | 10748000 Derived | -47187000 | -32968000 Derived | Source
|
| 2023 2023-01-01 – 2023-12-31 | 18511000 | 72986000 Derived | -54475000 | 4888000 Derived | -59363000 | -51166000 Derived | Source
|
| 2024 2024-01-01 – 2024-12-31 | 29431000 | 65596000 Derived | -36165000 | -6120000 Derived | -30045000 | -41188000 Derived | Source
|
| 2025 2025-01-01 – 2025-12-31 | 45151000 | 72097000 Derived | -26946000 | 12281000 Derived | -39227000 | -18930000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 45.2M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Revenue | 12398000 |
|
| 2023 | Revenue | 18511000 |
|
| 2024 | Revenue | 29431000 |
|
| 2025 | Revenue | 45151000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
53.4% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Year over year | No prior comparable period |
|
| 2023 | Year over year | 49.3% |
|
| 2024 | Year over year | 59% |
|
| 2025 | Year over year | 53.4% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -59.7% 2025
Net margin -86.9% 2025
Free cash flow margin -41.9% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Operating margin | -293.9% |
|
| 2023 | Operating margin | -294.3% |
|
| 2024 | Operating margin | -122.9% |
|
| 2025 | Operating margin | -59.7% |
|
| 2022 | Net margin | -380.6% |
|
| 2023 | Net margin | -320.7% |
|
| 2024 | Net margin | -102.1% |
|
| 2025 | Net margin | -86.9% |
|
| 2022 | Free cash flow margin | -265.9% |
|
| 2023 | Free cash flow margin | -276.4% |
|
| 2024 | Free cash flow margin | -139.9% |
|
| 2025 | Free cash flow margin | -41.9% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -18M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Operating cash flow | -32313000 |
|
| 2023 | Operating cash flow | -50578000 |
|
| 2024 | Operating cash flow | -40843000 |
|
| 2025 | Operating cash flow | -18012000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -18.9M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2022 | Free cash flow | -32968000 |
|
| 2023 | Free cash flow | -51166000 |
|
| 2024 | Free cash flow | -41188000 |
|
| 2025 | Free cash flow | -18930000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
195.8% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Liabilities / assets | 156% |
|
| 2023 | Liabilities / assets | 210% |
|
| 2024 | Liabilities / assets | 208% |
|
| 2025 | Liabilities / assets | 195.8% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
2.8× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2022 | Current assets / current liabilities | 0.53× |
|
| 2023 | Current assets / current liabilities | 1.42× |
|
| 2024 | Current assets / current liabilities | 2.02× |
|
| 2025 | Current assets / current liabilities | 2.8× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2022 2022-01-01 – 2022-12-31 | −USD 47.19 million Exact valueExact value: -47187000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 32.31 million Exact valueExact value: -32313000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 655,000 Exact valueExact value: 655000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 32.97 million Calculation and evidence-32313000 − 655000 USD Exact free cash flow: -32968000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | −USD 59.36 million Exact valueExact value: -59363000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 50.58 million Exact valueExact value: -50578000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 588,000 Exact valueExact value: 588000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 51.17 million Calculation and evidence-50578000 − 588000 USD Exact free cash flow: -51166000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 30.05 million Exact valueExact value: -30045000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 40.84 million Exact valueExact value: -40843000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 345,000 Exact valueExact value: 345000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 41.19 million Calculation and evidence-40843000 − 345000 USD Exact free cash flow: -41188000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 39.23 million Exact valueExact value: -39227000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 18.01 million Exact valueExact value: -18012000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 918,000 Exact valueExact value: 918000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 18.93 million Calculation and evidence-18012000 − 918000 USD Exact free cash flow: -18930000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
43 filings · 2,504 latest values · 2,504 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001826667, 1826667, edgar:1826667
Also known as MEDTECH ACQUISITION CORPORATION, MedTech Acquisition Corp, MedTech Acquisition Corporation, TRISALUS LIFE SCIENCES, INC., TRISALUS LIFE SCIENCES, INC., TriSalus Life Sciences, Inc.